Diversity Management, News and Updates
Originally Published by Johnson & Johnson Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart…
Originally Published by Johnson & Johnson Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have submitted Marketing Authorization Applications (MAAs) to the European Medicines Agency (EMA) seeking licensure for an investigational Ebola vaccine regimen for the prevention of Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. Two MAAs…
(Originally published Dec. 6 on LinkedIn) Today we learned that Novartis is among the top three companies in the world for high-quality science, notably topping the list of collaborative institutions in Nature Index’s Science 2017. Honored to be included in the @Nature Index for our contributions to science and academic…
(Originally published Dec. 6 on LinkedIn) Today we learned that Novartis is among the top three companies in the world for high-quality science, notably topping the list of collaborative institutions in Nature Index’s Science 2017. Honored to be included in the @Nature Index for our contributions to science and academic…
By Carolynn Johnson and Sheryl Estrada Women of Color in Pharma (WOCIP) hosted its first annual national conference in Princeton, N.J., on Nov. 6. As keynote speaker, Wanda Bryant Hope, chief diversity officer for Johnson & Johnson (No. 5 on the DiversityInc Top 50 Companies list), encouraged the almost 300…
Dr. Carsten Brunn Bayer (a DiversityInc Noteworthy Company) has announced the appointment of Dr. Carsten Brunnas as president of its pharmaceuticals business in the Americas, comprising the United States, Canada, Central and Latin America. In this role, Dr. Brunn will report to Dieter Weinand, member of the board of management…